Document Detail


Achieving LDL-C target levels: the role of statins.
MedLine Citation:
PMID:  11268713     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Epidemiological and clinical studies have clearly established the link between elevated low-density lipoprotein cholesterol (LDL-C) and coronary heart disease (CHD). Consequently, treatment guidelines have been developed that identify LDL-C as a causative factor for CHD and as a target for lipid-lowering therapy. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are considered the drugs of choice for lowering LDL-C in patients with hypercholesterolaemia. However, despite the proven efficacy of statins in reducing LDL-C, many patients do not achieve recommended LDL-C target levels. Surveys suggest that patients do not receive the appropriate drugs in adequate dosage to reach LDL-C target values. Success in achieving targets is lowest in patients at the highest risk, i.e. those with established CHD. The introduction of more potent HMG-CoA reductase inhibitors, or the use of higher doses of older statins, should allow more patients to achieve LDL-C target levels.
Authors:
J M Lablanche
Related Documents :
10996333 - Cardiovascular risk changes after lipid lowering medications: are they predictable?
12069383 - Lipid formulation as a drug carrier for drug delivery.
24372243 - Mesoporous materials and nanocrystals for enhancing the dissolution behavior of poorly ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current medical research and opinion     Volume:  16     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2001  
Date Detail:
Created Date:  2001-03-27     Completed Date:  2001-07-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  285-95     Citation Subset:  IM    
Affiliation:
Service de Cardiologie B et Hemodynamique, Hôpital Cardiologique, 59037 Lille, France. jmlablanche@chru-lille.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / chemistry,  pharmacology,  therapeutic use*
Cholesterol, LDL / blood*,  drug effects*
Coronary Disease / etiology*,  prevention & control*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / chemistry,  pharmacology,  therapeutic use*
Hypercholesterolemia / complications*,  drug therapy*
Patient Selection
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Twenty-third Annual San Antonio Breast Cancer Symposium.
Next Document:  Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.